Skip to search formSkip to main contentSkip to account menu

glucosyl-ifosfamide mustard

Known as: Beta-D-Glucosyl-Ifosfamide Mustard, Glufosfamide, glc-IPM 
A compound consisting of the mustard agent ifosforamide conjugated to glucose, with potential alkylating activity. Glufosfamide is cleaved by… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Antineoplastic Agents, AlkylatingGlucoseIfosfamideProdrugs
D 19575

Narrower (1)

beta-D-glucosylisophosphoramide mustard

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Oxazaphosphorines belong to a group of alkylating agents. Mafosfamide cyclohexylamine salt (D-17272), 4-hydro-peroxy… 
2009
2009
A Phase 2 Trial of Glufosfamide in Combination With Gemcitabine in Chemotherapy-Naive Pancreatic Adenocarcinoma
Objectives:A dose-escalation study of glufosfamide plus gemcitabine showed that the combination could be administered safely at… 
Review
2008
Review
2008
Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents.
BACKGROUND Cancer control by radiotherapy (RT) can be improved with concurrent chemotherapy. Outpatient strategies for sarcomas… 
2008
2008
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma
AbsractPurposeTo evaluate safety and pharmacokinetics and to establish the maximum tolerated dose of glufosfamide when… 
2007
2007
A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo.
Glufosfamide is an alkylating agent consisting of iphosphoramide mustard conjugated to glucose that is currently included in… 
Review
2005
Review
2005
Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
2004
2004
Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent.
BACKGROUND Glufosfamide is a novel alkylating agent in which the active metabolite of isophosphoramide mustard is glycosidically… 
Review
2002
Review
2002
Glufosfamide (Baxter Oncology).
Glufosfamide is a sugar phosphamide alkylating agent under development by Baxter Oncology (formerly ASTA Medica) as a potential… 
2002
2002
In vitro activity of glufosfamide in childhood acute leukemia.
Glufosfamide is a new agent for cancer chemotherapy. The objective of the study was the comparison of the in vitro drug… 
1996
1996
Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent β-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of…
Abstract β-D-Glucosylisophosphoramide mustard (β-DGlc-IPM) is a new, potential chemotherapeutic agent currently under… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)